Secondary cytoreduction in ovarian cancer: who really benefits?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology,General Medicine
Link
http://link.springer.com/article/10.1007/s00404-018-4915-1/fulltext.html
Reference49 articles.
1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2018. CA Cancer J Clin 67:7
2. Conte PF, Bruzzone M, Carnino F (1991) Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 9(4):658–663
3. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496
4. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483
5. Petrillo M, Amadio G, Salutari V et al (2016) Impact of Bevacizumab containing first line chemotherapy in recurrent disease in epithelial ovarian cancer. A case-control study. Gynecol Oncol. 142(2):231–236
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium;Annals of Surgical Oncology;2022-09-09
2. Prognostic factors for survival in patients with lung metastases from gynaecological tract cancers;Interactive CardioVascular and Thoracic Surgery;2021-08-03
3. Hyperthermic intraperitoneal chemotherapy in locally advanced and recurrent ovarian carcinoma: surgical and oncological outcomes in the Indian public healthcare system;Future Oncology;2021-05
4. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience;Cancers;2021-01-29
5. Surgical outcomes of segmental ureteral resection with ureteroneocystostomy after major gynecologic surgery;European Journal of Surgical Oncology;2020-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3